Drug Profile
VXA G1.1 NN
Alternative Names: GI.1 oral vaccine tablet - Vaxart; GI.1 vaccine - Vaxart; H1N1 (high dose) Oral Vaccine Tablet; H1N1 (low dose) Oral Vaccine Tablet; Monovalent GI.1 tableted vaccine - Vaxart; Norovirus GI.1 vaccine; VXA-G1-1-NN; VXA-G1.1-NNLatest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator Vaxart
- Class DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Norovirus infections
Most Recent Events
- 31 Dec 2023 Vaxart in collaboration with Bill & Melinda Gates Foundation completes enrolment in a phase-I trial for Norovirus infections in December 2023
- 06 Sep 2023 Efficacy data from a phase II trial in Norovirus infections (Prevention) released by Vaxart
- 06 Sep 2023 Vaxart plans a phase III registrational trial for Norovirus infections (Prevention)